One third of late-onset epilepsy have no known etiology. Cognitive symptoms are common with LOE and a third of these patients have mild cognitive impairment. Some patients with LOE have transient epileptic amnesia (TEA), while others develop neurodegenerative diseases such as Alzheimer's disease or dementia with Lewy bodies. Autoimmune causes have variable clinical presentations.
Incorporate findings from the NINDS workshop entitled, "Metabolism-based Therapies for Epilepsy" (Nov 9. 2020)
The current benchmarks never say the words "cure epilepsy". It is vaguely suggested by Area II, component E, but why be vague? We want to CURE EPILEPSY. Lets say that loud and clear, right?
Incorporate ethics approaches and use human values to guide innovation in research and technology for drug resistant epilepsy (DRE).
By integrating clinical care and research—the standard for decades in pediatric oncology—we will get on a path where we will start seeing improvements in the quality of life for all those living with and too often dying from epilepsy.... more »
For example, a patient with as yet unexplained non-acquired epilepsy should be considered to have genetic epilepsy until proven otherwise and appropriately evaluated. If the first line of evaluation is unrevealing he or she should have an iterative re-analysis of cause in tandem with empiric therapy.... more »
The lowest hanging fruit for epilepsy models is to use CRISPR-knock-in (KI) strategies to create mice expressing human gene variants rather than simply presuming gene knockout or over-expression will accurately model a loss- or gain-of-function mutation.... more »
This should be a clear mandate for future and collaborative investigation in epilepsy, as it provides an opportunity to bring in scientists from disciplines outside of the epilepsy field.